Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
FDA extends the effective date for the final resolution of DESI 7661 regarding estrogen-androgen fixed-combination drug products, providing additional time for manufacturers to comply.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Manufacturers of estrogen-androgen fixed-combination drug products subject to DESI 7661. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; refer to the full Federal Register notice for the new effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The effective date for the final resolution of DESI 7661 has been extended for a second time.
Who it affects
Manufacturers of estrogen-androgen fixed-combination drug products subject to DESI 7661.
What you must do
Review the extension notice to confirm the new effective date and ensure ongoing compliance with any interim requirements.
Deadline
Not specified in the excerpt; refer to the full Federal Register notice for the new effective date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
- FDA to require diversity plan for clinical trials - nature.com
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments